We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-transfection Launches Polyplus in vivo Consortium
News

Polyplus-transfection Launches Polyplus in vivo Consortium

Polyplus-transfection Launches Polyplus in vivo Consortium
News

Polyplus-transfection Launches Polyplus in vivo Consortium

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Polyplus-transfection Launches Polyplus in vivo Consortium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Polyplus-transfection has announced that it is setting up a group called the "Polyplus in vivo Consortium". This group will be developed on a user group model and bring together research scientists and clinicians in an international network of users of Polyplus-transfection's gene therapy reagents.

Polyplus-transfection expects the new group to increase the number of clinical trials using its synthetic gene transfer reagents and accelerate their development.

The Polyplus in vivo Consortium aims at letting users of Polyplus-transfection's products and solutions share their experience to accelerate the implementation of clinical trials and give them access to Polyplus-transfection's latest technology.

The company plans to organize regular meetings and workshops and will actively support the Polyplus in vivo Consortium members in their preclinical and clinical therapeutic projects. Members will benefit from personalized support, from Polyplus-transfection's expertise regarding in vivo delivery as well as preferential conditions for products used for therapeutic development. Among other services, Polyplus-transfection will supply appropriate certificates of analysis for preclinical and toxicology studies.

Polyplus-transfection's in vivo-jetPEI compound will play a key role in the Consortium. It is derived from the synthetic molecule polyethylenimine (PEI) for which Polyplus-transfection holds the exclusive worldwide license for the transfection of nucleic acids. In vivo-jetPEI is widely used for in vivo experiments. It allows intracellular delivery of nucleic acids and has become a benchmark in gene delivery.

"The Polyplus in vivo Consortium will make research and development of gene therapy applications easier," said Joelle Bloch, CEO of Polyplus-transfection.

"The project meets a real need that was revealed by the first clinical research teams using our products. It will allow Polyplus-transfection to build a true network where users of our transfection reagents can exchange know-how and experience. This network will help our customers get their clinical trials under way and also help Polyplus-transfection develop solutions that suit users' needs," Bloch added.

Advertisement